Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised GeneraLife in connection with its acquisition of Livio Group
Mandate

Vinge has advised GeneraLife in connection with its acquisition of Livio Group

September 13, 2022 EU, Competition and Regulatory M&A Employment and Benefits IT, Telecommunications and Outsourcing Real Estate and Construction Banking and Finance Restructuring and Insolvency

Vinge has advised GeneraLife, one of Europe's largest fertility clinic groups and owned by KKR, in connection with its acquisition of Livio Group.

Livio is the largest fertility clinics group in the Nordics, present with 9 clinics in Sweden, Norway and Iceland. The acquisition also encompasses the Livio's own gamete bank, Livio Egg and Sperm Bank, with a sales hub in Denmark.

Vinge's team consisted of responsible partner Matthias Pannier and associates, Samra Baytar, Stina Bengtsson, Olivia Belding, Elias Bohlin (M&A), Trine Osen Bergqvist, Johan Wahlbom, Jakob Jeanrond, Victoria Fredén, Alva Chambert (Antitrust), Christoffer Nordin, Mika Jordan (Regulatory & Agreements), Rebecka Målquist (IP), Frida Ställborn, Karolina Cohrs (Real Estate), Calle Tengwall Pagels (Banking & Finance), Gustav Lindgren (Employment), Karolina Fuhrman (IT & GDPR) and Jessica Henning (Project Assistance).

Related

Vinge advises Pricer AB in connection with its issuance of senior unsecured bonds and early redemption

 Vinge advises Pricer AB (publ) in connection with its issuance of floating rate senior unsecured bonds of SEK 300 million within a framework of SEK 500 million and early redemption of existing bonds.
December 10, 2024

Vinge advises Carasent in connection with the listing on Nasdaq Stockholm

 Vinge advises Carasent AB (publ) in connection with the listing on Nasdaq Stockholm. The listing is made through a reverse cross-border merger, whereby Carasent AB takes over Carasent ASA, previously listed on Oslo Stock Exchange.
December 09, 2024

Vinge has advised Apotea in connection with its listing on Nasdaq Stockholm

 Vinge has advised Apotea AB (publ) (“Apotea”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on November 26, 2024 and the first day of trading is December 6, 2024.
December 06, 2024